## INTERLEUKIN-33 (IL-33) AS A NEW MARKER OF PULMONARY SARCOIDOSIS.

W. Naumnik<sup>1,2</sup>, W. Niklińska<sup>3</sup>, M. Ossolińska<sup>1</sup>, E.Chyczewska<sup>1</sup>

<sup>1</sup>Department of Lung Diseases, Medical University of Bialystok, Poland

<sup>2</sup>Department of Clinical Molecular Biology, Medical University of Bialystok, Poland

<sup>3</sup>Department of Histology and Embryology, Medical University of Bialystok, Poland

The mechanisms of sarcoidosis (BBS, Besniera-Boeck-Schaumann disease) remains incompletely understood, although recent observations suggested an important contribution of IL-33. Recently many studies revealed that IL-33 is associated with suppressing Th1 responses, which play major role in patients with BBS. So far, there is no data about concentration of IL-33 in patients with BBS. We wanted to relate concentration of IL-33 to interleukin-18 (IL-18) - a well-known marker of BBS activity.

The aim of the study was to evaluate the concentration (Elisa) of IL-33 and IL-18 in BALF (BronchoAlveolar Lavage Fluid) in BBS patients. We examined 24 BBS patients (stage II). The age matched control group consisted of 24 healthy subjects. The levels of IL-33 and IL-18 in BALF were higher in BBS patients than in control group [ IL-33: 4.8 (0.1-12.5) vs 3.38 (0.6-56.9) pg/ml, p = 0.024; IL-18: 33.19 (5.7-122) vs 10.83 (1.9 – 45.8) pg/ml, p = 0.002 ]. In BBS group we found correlations between the levels of IL-33 and IL-18 (R=0.606, p=0.002) as well as IL-33 and DLCO (R=-0.5, p=0.035). Receiver-operating characteristic (ROC) curves were applied to find the cut-off the serum levels of IL-33 and IL-18 in BALF (BBS vs Healthy: IL-33 2.699 pg/ml, IL-18 16.436 pg/ml). We conclude that IL-33 may present as an important factor of pulmonary BBS activity.